Literature DB >> 3044073

Autoantibodies to the insulin receptor as a cause of autoimmune hypoglycemia in systemic lupus erythematosus.

D E Moller1, R E Ratner, D G Borenstein, S I Taylor.   

Abstract

A 52-year-old black woman presented with clinical features of systemic lupus erythematosus (SLE) and severe fasting hypoglycemia. Hypoglycemia was secondary to autoantibodies to the insulin receptor that were detected in the patient's serum. There were no anti-insulin antibodies, and other causes of hypoglycemia were excluded. Treatment with high-dose glucocorticoids resulted in restoration of euglycemia associated with resolution of circulating anti-receptor antibodies and parallel improvement in clinical and laboratory features of SLE. This case is compared with other cases of autoimmune hypoglycemia due to anti-receptor antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044073     DOI: 10.1016/0002-9343(88)90436-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  Antibodies directed to the insulin receptor. Clinical aspects and applications to the study of insulin action.

Authors:  R De Pirro; P Borboni; M A Marini; A Montemurro; G Sesti; R Lauro
Journal:  J Endocrinol Invest       Date:  1990-12       Impact factor: 4.256

2.  Autoantibodies to the insulin receptor are infrequent findings in type 1 (insulin-dependent) diabetes mellitus of recent onset.

Authors:  N Rochet; J L Sadoul; B Ferrua; J Kubar; J F Tanti; P Bougnères; B Vialettes; E Van Obberghen; Y Le Marchand-Brustel; P Freychet
Journal:  Diabetologia       Date:  1990-07       Impact factor: 10.122

3.  Insulin antibodies and hypoglycemia in diabetic patients. Can a quantitative analysis of antibody binding predict the risk of hypoglycemia?

Authors:  M R Kim; L R Sheeler; N Mansharamani; M T Haug; C Faiman; M K Gupta
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

4.  A case of systemic lupus erythematosus presenting as hypoglycemia due to anti-insulin receptor antibodies.

Authors:  Yuuka Kato; Yoshiro Ichiki; Yasuo Kitajima
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.